---
title: "Weekly Recap: US$30M AstraZeneca upfront and SYS6063 Phase I start"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296034254.md"
description: "CSPC Pharmaceutical Group received a US$30 million upfront payment from AstraZeneca on August 12, 2026, under their collaboration agreement. Additionally, CSPC initiated a Phase I trial in China for SYS6063, a drug targeting relapsed or refractory systemic lupus erythematosus."
datetime: "2026-08-16T23:13:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296034254.md)
  - [en](https://longbridge.com/en/news/296034254.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296034254.md)
generator: "portal-rs"
---

# Weekly Recap: US$30M AstraZeneca upfront and SYS6063 Phase I start

CSPC Pharmaceutical Group Limited (HKEX:1093) bolstered its pipeline and cash position after receiving a US$30 million upfront from AstraZeneca on Aug 12, 2026, as it also initiated a Phase I trial in China for SYS6063 targeting relapsed/refractory systemic lupus erythematosus.

**Previous Week Recap**

-   **CSPC 1093 Receives $30 Million Upfront**: CSPC Pharmaceutical Group (1093) received a US$30 million upfront payment from AstraZeneca on August 12, 2026, recorded under their collaboration agreement. Reuters
-   **CSPC Starts Phase I SYS6063 Trial**: CSPC Pharmaceutical (1093) started a Phase I trial in China for SYS6063 targeting relapsed/refractory systemic lupus erythematosus (SLE). Reuters

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.

### Related Stocks

- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)
- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)

## Related News & Research

- [CSPC Pharma FY26 H1 profit attributable to shareholders more than doubled to RMB 6.09 billion; revenue rises 40.1% to RMB 18.59 billion](https://longbridge.com/en/news/296433558.md)
- [CSPC PHARMA  Shares Rise 15% as Phase Ib/II Clinical Trial of SYS 6090 Injection for Hepatocellular Carcinoma Launches at First Center in China](https://longbridge.com/en/news/296423040.md)
- [CSPC PHARMA  1H26 Net Profit Surges Nearly 1.4x, Interim DPS Up 28.6% to HKD0.18](https://longbridge.com/en/news/296435690.md)
- [M Stanley Raises CSPC PHARMA  TP to HKD12, Rating Overweight](https://longbridge.com/en/news/296557755.md)
- [AstraZeneca Reports Mixed Lung Cancer Trial Outcomes From Three Pivotal Studies](https://longbridge.com/en/news/296114723.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**